GlassScriptPhysician profile
Leslie D Butler
NPI 1790752483
$4,202.36
in general payments reported to CMS, 2019-2025
25 companies · $485 in 2025
The $485 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $508 · 2022: $1,034 · 2023: $1,031 · 2024: $1,144 · 2025: $485.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,659.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,066.56 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $470.23 | 2021-2024 | |
| Glaxosmithkline, LLC. | $363.67 | 2021-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $265.67 | 2023-2024 | Spravato |
| Sanofi-Aventis U.S. LLC | $251.35 | 2021-2023 | |
| Amgen INC. | $186.65 | 2021-2023 | Otezla, Repatha |
| Lilly USA, LLC | $186.51 | 2021-2024 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $170.93 | 2022-2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $158.85 | 2022-2024 | Rybelsus, Ozempic |
| Paratek Pharmaceuticals, INC. | $138.96 | 2025 | Nuzyra, Xhance |
| Medtronic, INC. | $133.72 | 2022-2024 | Intellis Adaptivestim |
| Astellas Pharma US INC | $125.00 | 2023 | Veozah |
| Pfizer INC. | $122.37 | 2021-2025 | |
| Phathom Pharmaceuticals, INC. | $117.45 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $83.90 | 2023 | Quviviq |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $83.90 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.46 | 2024-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.99 | 2021 | |
| Amarin Pharma, INC. | $41.91 | 2021-2022 | |
| Dexcom, INC. | $38.49 | 2022-2024 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $22.75 | 2024 | |
| Inspire Medical Systems, INC. | $20.73 | 2023 | Inspire |
| Novartis Pharmaceuticals Corporation | $18.66 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $17.75 | 2023 | Nuedexta |
| Axsome Therapeutics, INC. | $13.90 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leslie Butler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.